Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, Merck Collaborating on Lung Imaging Tech Trial

NEW YORK (GenomeWeb News) – GE Healthcare said today it has signed an agreement giving the drugmaker Merck access to a molecular imaging agent GE is developing for high-speed, quantitative lung imaging.
 
The company said the collaborators will evaluate GE Healthcare’s Spin Signal Technology to determine if it can help researchers study the functioning of diseased lungs using modified xenon gas in conjunction with magnetic resonance imaging scans.
 
The companies will be able to assess the effects of potential therapeutics in real-time in animal models, GE said.
 
Kim Gallagher, who is head of external scientific affairs in the medical diagnostics division of GE Healthcare, said that the agreement gives Merck access to the SST and to the modified xenon trial data and will “monitor its potential and plan for its possible incorporation in therapy trials.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.